Detail akcie Epistem Hold online

Business Summary: genedrive plc is a United Kingdom-based pharmacogenetic testing company. The Company is engaged in developing and commercializing a rapid, versatile, simple to use and robust point-of-need pharmacogenetic platform for the diagnosis of genetic variations. The Company’s products include Genedrive MT-RNR1 ID Kit, Genedrive System, and Genedrive CYP2C19 ID Kit. The Company’s flagship product Genedrive MT-RNR1 ID Kit is a single-use disposable cartridge that circumvents the requirement for cold chain logistics by providing temperature stable reagent test kits for use on their proprietary test platform. The Genedrive System is a rapid thermocycler and signal detection system, enabling PCR and isothermal based amplification techniques. It is a semi- automated system used for qualitative in vitro molecular diagnostic tests. Its Genedrive CYP2C19 ID Kit Molecular point-of-care test for rapid CYP2C19 genotyping in time-critical emergency care settings.
Financial Summary: BRIEF: For the fiscal year ended 30 June 2025, Genedrive PLC revenues increased 90% to L954K. Net loss decreased 26% to L5.2M. Revenues reflect United Kingdom segment increase from L411K to L931K, Rest of world segment increase of 31% to L21K. Lower net loss reflects Diagnostics Segment loss decrease of 11% to L3.3M. Basic Earnings per Share excluding Extraordinary Items increased from -L0.05 to -L0.01.